BLA 125547 · Eli Lilly CO
Portrazza
Necitumumab · Intra-Articular, Intramuscular, Intravitreal
NovelLast checked: Nov 20, 2026Latest source record: Nov 24, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Nov 24, 2015
Approved uses
1
Original approval plus efficacy supplements
Registered trials
23
2 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 24, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewSummary Review
1 products under this application
- PORTRAZZA · NECITUMUMAB 800MG/50ML · INJECTABLE, INTRA-ARTICULAR, INTRAMUSCULAR, INTRAVITREAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Necitumumab" as an intervention, any sponsor and status, largest first.
- First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-CisplatinPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00981058 · 1,093 participants · Start Jan 7, 2010 · Primary completion Jun 17, 2013
Drug: Necitumumab; Gemcitabine and 1 more · For: Non Small Cell Lung Cancer
Sites: Chandler, Arizona; Fayetteville, Arkansas; Sacramento, California · 182 sites in all
- First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-CisplatinPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00982111 · 633 participants · Start Nov 2, 2009 · Primary completion Nov 14, 2012
Drug: Pemetrexed; Cisplatin and 1 more · For: Non Small Cell Lung Cancer
Sites: Nyack, New York; Kogarah, Australia; Hobart, Australia · 101 sites in all
- Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)Active, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT03944772 · 247 participants · Start Jun 25, 2019 · Primary completion May 6, 2025
Drug: Osimertinib; Savolitinib and 11 more · For: Non-Small Cell Lung Cancer
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 47 sites in all
- A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)Pivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01763788 · 192 participants · Start May 7, 2013 · Primary completion Jun 28, 2017
Drug: Necitumumab; Gemcitabine and 1 more · For: Squamous Non-small Cell Lung Cancer
Sites: Aichi, Japan; Chiba, Japan; Ehime, Japan · 20 sites in all
- A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01769391 · 167 participants · Start Jan 2013 · Primary completion Apr 2015
Drug: Necitumumab; Paclitaxel and 1 more · For: Squamous Non Small Cell Lung Cancer
Sites: Jonesboro, Arkansas; Los Angeles, California; Sacramento, California · 51 sites in all
- Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase InhibitorActive, not recruiting
National Cancer Institute (NCI)NIH
NCT02496663 · 138 participants (planned) · Start May 11, 2016 · Primary completion Jun 30, 2027
Drug: Necitumumab; Osimertinib · For: Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Stage IV Lung Cancer AJCC v8
Sites: Duarte, California; Palo Alto, California; Sacramento, California · 15 sites in all
- A Study of Necitumumab Monotherapy and the QT/QTc Interval in Patient With Advanced Solid TumorsCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT01624467 · 75 participants · Start Aug 2012 · Primary completion May 2014
Drug: Necitumumab · For: Solid Tumors
Sites: Ann Arbor, Michigan; Detroit, Michigan; Las Vegas, Nevada · 8 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT02451930 · 71 participants · Start Sep 4, 2015 · Primary completion Jan 26, 2017
Drug: Necitumumab; Pembrolizumab · For: Stage IV Non-Small Cell Lung Cancer
Sites: Fort Myers, Florida; St. Petersburg, Florida; Nashville, Tennessee · 16 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer.
Besse B, Garrido P, Cortot AB, et al. · Lung Cancer 2020 · Clinical Trial, Phase I, Multicenter Study
- Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial.
Thatcher N, Hirsch FR, Luft AV, et al. · Lancet Oncol 2015 · Clinical Trial, Phase III, Comparative Study
- Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.
Goldstein DA, Chen Q, Ayer T, et al. · JAMA Oncol 2015 · Clinical Trial, Phase III, Multicenter Study
- ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib.
Riess JW, de Langen AJ, Ponce S, et al. · JCO Precis Oncol 2025 · Clinical Trial, Phase II, Multicenter Study
- A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer.
Besse B, Barlesi F, Demedts I, et al. · Lung Cancer 2019 · Clinical Trial, Phase I, Multicenter Study
- Evaluation of the effect of necitumumab on the corrected QT interval in patients with advanced solid tumors.
Smith DC, Powderly J, Lee JJ, et al. · Cancer Chemother Pharmacol 2016 · Clinical Trial, Phase II, Multicenter Study
Sponsor: Eli Lilly
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.